Somali
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Qaybaha Alaabta
Alaabta sifaysan
Kiniiniyada Lenopril oo Awood siinaysa Xakamaynta Cadaadiska Dhiiga iyo Caafimaadka Wadnaha

Kiniiniyada Lenopril oo Awood siinaysa Xakamaynta Cadaadiska Dhiiga iyo Caafimaadka Wadnaha
Telmisartan Ka Hortagga Dhiig-karka Ka Wanaagsan Kahortagga Kelyaha

Telmisartan oo ka roon antihypertensive Ka ilaalinta kelyaha
Flumazenil A Xulashada GABAA Soo Dhaweeye Kahortaga iyo Codsiyada Daweynta

Flumazenil A Xulashada GABAA Soo Dhaweeye Kahortaga iyo Codsiyada Daweynta
Trametinib Kinase Inhibitor Bartilmaameedka BRAF V600 Kansarka Wanaagsan ee Mutation-ka

Trametinib Kinase Inhibitor Bartilmaameedka BRAF V600 Kansarka Wanaagsan ee Mutation-ka
Dabrafenib Daawaynta Bartilmaameedsan ee Kansarka-Braf-Isbedeshay

Dabrafenib Daawaynta Bartilmaameedsan ee Kansarka BRAF-Is-beddelay
Tirzepatide Dual GLP-1 iyo GIP Qabayaha Agonist ee Maareynta Miisaanka iyo Xakamaynta Glycemic

Tirzepatide Dual GLP-1 iyo GIP Soo Dhaweeyaha Agonist ee Maareynta Miisaanka iyo Xakamaynta Glycemic
Kicinta caloosha ee Cisapride ee dheef-shiid kiimikaadka iyo cilladaha dheefshiidka

Kicinta caloosha ee Cisapride ee dheef-shiid kiimikaadka iyo cilladaha dheefshiidka
YK-11 SARM ee Awooda leh ee Dhismaha Murqaha, Helitaanka Awooda, iyo Joojinta Myostatin

YK-11 SARM ee Awooda leh ee Dhismaha Murqaha, Helitaanka Awooda, iyo Joojinta Myostatin
Ostarine (MK-2866) SARM-gaaban ee Kobaca Murqaha, Burburka Dufanka, iyo Dib-u-soo-celinta Jirka

Ostarine (MK-2866) SARM-gaaban ee Kobaca Murqaha, Burburka Dufanka, iyo Dib-u-soo-celinta Jirka
MK-677 Isku-dhafka Gaarka ah ee Kobaca Murqaha, Adkeysiga, iyo Soo kabashada

MK-677 Isku-dhafka Gaarka ah ee Kobaca Murqaha, Adkeysiga, iyo Soo kabashada
0102030405
Trametinib Kinase Inhibitor Bartilmaameedka BRAF V600 Kansarka Wanaagsan ee Mutation-ka
Trametinib Kinase Inhibitor Bartilmaameedka BRAF V600 Kansarka Wanaagsan ee Mutation-ka

Trametinib Kinase Inhibitor Bartilmaameedka BRAF V600 Kansarka Wanaagsan ee Mutation-ka

Qiimaha tixraaca: USD 8-15/g

  • Magaca Alaabta Trametinib
  • CAS Maya. 871700-17-3
  • MF C26H23FIN5O4
  • MW 615.402623
  • Cufnaanta 1.743
  • barta dhalaalaysa 293-303°C
Nala soo xiriir
faahfaahinta alaabta

Sharaxaad faahfaahsan

Trametinib waa kinase inhibitor awood leh oo xulashada ugu horayn loo isticmaalo daawaynta melanoma aan la soo celin karin ama metastatic melanoma oo leh isbeddelka BRAF V600, iyo sidoo kale noocyo gaar ah oo horumarsan ama metastatic ah oo aan yareyn kansarka sanbabada. Maqaalkani waxa uu sahamiyaa habka ficilka, calaamadaha kiliinikada, iyo faa'iidooyinka trametinib ee daaweynta kansarka BRAF V600 mutation-positive.

I. Fahamka Trametinib:
A. Kinase inhibitor afka ah, awoodda leh, iyo xulashada
B. Waxay ka tirsan tahay fasalka horjoogayaasha MEK
C. Wuxuu xannibaa dhaqdhaqaaqa kinase ee MEK1 iyo MEK2
D. Waxay joojisaa calaamadaynta ERK1 iyo ERK2

II. Tilmaamaha Caafimaadka:
A. Melanoma aan la soo saari karin ama metastatic melanoma ah oo xajinaysa isbeddelka BRAF V600:
Daaweynta isku dhafka ah ee dabrafenib mesylate
B. Daaweynta adjuvant ee qalliinka ka dib ee BRAF V600 melanoma-ka beddelka-togan:
Daaweynta adjuvant ee dabrafenib mesylate ka dib dib u soo celin dhamaystiran

17161152266097be

III. Doorka Kansarka Sambabada Unug Yar ee Aan Yarayn:

A. Kansarka sambabada unugyada aan yareyn oo ah sababta ugu weyn ee cudurrada iyo dhimashada

B. Heerka beddelka hidda-wadaha BRAF iyo faafitaanka beddelka BRAF V600E

C. Trametinib's saamaynta xannibaadda ee unugyada BRAF V600 beddelka-positive ee melanoma


IV. Habka Waxqabadka:

A. Joojinta dib-u-noqoshada mitogen-firfircoon ee kinase-sharciyeed ka baxsan unugga (MEK) 1 iyo MEK2

B. Saamaynta jidka MAPK iyo borotiinka MEK

C. Joojinta faafinta unugyada iyo dariiqa hoose ee ERK


V. Daaweynta Adjuvant Therapy:

A. Faa'iidooyinka daawaynta isku dhafka ah ee la beegsaday Dabrafenib iyo Trametinib

B. Faa'iidooyinka badbaadada xorta ah ee soo noqnoqda ee muddada dheer, waarta ee heerka khatarta sare leh ee III BRAF bukaannada melanoma-ga ah



Trametinib, oo ah xannibaadaha kinase ee la beegsaday, ayaa muujinaya waxtarka muhiimka ah ee daaweynta kansarka sanbabada ee BRAF V600, gaar ahaan melanoma aan la daboolin ama metastatic iyo noocyo gaar ah oo kansarka sambabada unugyada yaryar. Nidaamkeeda ficilka, joojinta dhaqdhaqaaqa MEK1 iyo MEK2 kinase, waxay keenaysaa joojinta dariiqa ERK ee hoose iyo xakamaynta faafinta unugyada. Trametinib, oo ay weheliso dabrafenib mesylate, waxay siisaa faa'iidooyin daweyn labadaba goobaha horumarsan iyo kuwa adjuvant ee bukaanka melanoma ee BRAF V600.
Nala soo xidhiidh si aad u hesho talobixin daawaynta iyo macluumaadka qiimaha jumlada si kor loogu qaado daryeelka bukaanka.

Tilmaamid

171611254334271z